Pacira BioSciences, Inc. PCRX
36.49 USD +0.03 (+0.08%)
At closeNov 10, 2026, 4:28 PM EST
36.49 0.00 0.00%
After hours · Nov 10, 4:28 PM ET
36.45 Day range 36.50
18.80 52-week range 36.67
- YTD
- +41.00%
- 1 year
- +58.17%
News
benzinga.com Pacira BioSciences Withdraws 2026 Guidance Pending Proposed Merger With Viatris As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the "Company" or "Pacira"), entered into the Agreement and Plan of Merger (the "Merger Agreement")
prnewswire.com Viatris Reports Third-Quarter 2026 Financial Results Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in…
globenewswire.com INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
prnewswire.com Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders? /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
prnewswire.com INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for
benzinga.com Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
benzinga.com Top 3 Health Care Stocks That May Fall Off A Cliff In October Option Care Health, Pacira Biosciences and HealthStream show overbought RSI levels above 83, warning momentum-focused investors.
benzinga.com Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5 Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.
benzinga.com RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5 RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $25 to $36.5.
benzinga.com This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.
benzinga.com CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.- benzinga.com HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5 HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Neutral and lowers the price target from $38 to $36.5.
benzinga.com Nasdaq Falls Over 300 Points as Oil Prices Surge: Investor Sentiment Weakens, Fear & Greed Index Remains in ‘Fear’ Zone Markets stayed fearful as index fell to 38; Dow gained, S&P/Nasdaq slipped amid oil surge and Iran tensions. PepsiCo and Pacira shares rose.
benzinga.com Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target Jefferies analyst Glen Santangelo downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and announces $36 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday's regular session. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) stock rose…
benzinga.com Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.
benzinga.com Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
benzinga.com Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.- benzinga.com Truist Securities Maintains Buy on Pacira BioSciences, Raises Price Target to $31 Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $31.
benzinga.com Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32 Oppenheimer analyst Les Sulewski initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Outperform rating and announces Price Target of $32.- benzinga.com Leerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28 Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.
- benzinga.com Pacira Biosciences Publishes 2-Yr Phase 1 Results In Annals Of Rheumatic Diseases For PCRX-201 Gene Therapy In Moderate To Severe Knee Osteoarthritis, Showing Tolerability And Improvements In Pain, Stiffness, And Function — A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —— Exploratory clinical outcome measures…
- benzinga.com RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25 RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $24 to $25.
benzinga.com Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33 Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $32 to $33.- benzinga.com Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est Pacira BioSciences (NASDAQ:PCRX) lowers FY2026 sales outlook from $745.000 million-$770.000 million to $735.000 million-$760.000 million vs $766.384 million estimate.
- benzinga.com Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.65 by 12.31 percent. This is a 1.35 percent decrease over earnings of…
benzinga.com Pacira BioSciences Successfully Transitions PCRX-201 To A Scalable Commercial Manufacturing Process In The U.S.; Topline Data From Part A Of Phase 2 ASCEND Study Remains On Track For End Of 2026 With drug product from the new manufacturing process now available, the first patient has been enrolled in Part B of the Phase 2 ASCEND study. Enrollment in Part A of ASCEND concluded in June, with…- benzinga.com HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $38 price target.
- benzinga.com Pacira BioSciences Says UnitedHealthcare Now Provides Separate Reimbursement For EXPAREL Across Outpatient Settings, Including Hospital Outpatient Departments And Ambulatory Surgery Centers -- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the…
benzinga.com Pacira BioSciences Divests Iovera To Zimmer Biomet For Up To $140M Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the divestiture of…- benzinga.com Pacira BioSciences Announces Findings From Real-World Study Evaluating Outcomes Associated With Use Of EXPAREL Following Outpatient Total Shoulder Arthroplasty In Medicare Advantage Patients Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL useBRISBANE, Calif., May 27, 2026 (GLOBE…
- benzinga.com RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24 RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $22 to $24.
benzinga.com Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $32 Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $32.- benzinga.com Pacira BioSciences Q1 2026 Earnings Call Transcript
- benzinga.com Pacira BioSciences Affirms FY2026 Sales Guidance of $745.000M-$770.000M vs $759.317M Est Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in millions)2026 Financial GuidanceAmountEXPAREL net product sales$600 to $620Total revenues$745 to…
- benzinga.com Pacira BioSciences Q1 Adj. EPS $0.60 Beats $0.56 Estimate, Sales $177.376M Beat $173.325M Estimate Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.56 by 7.14 percent. This is a 3.23 percent decrease over earnings of…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Pacira BioSciences Announces Findings From A Study Evaluating The Clinical And Economic Impact Of Exparel On Opioid Use, Healthcare Resource Utilization, And Total Medical Costs Following Outpatient Total Hip Arthroplasty Among Medicare Patients The data were presented at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting, hosted by the American Society of Regional Anesthesia and Pain Medicine (ASRA), held from April…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Pacira BioSciences Presents Data From Three Studies Supporting Economic Value Of EXPAREL In Total Hip Arthroplasty And Total Knee Arthroplasty Procedures Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today presented data from three…
- benzinga.com Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $25 Barclays analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight and lowers the price target from $27 to $25.
benzinga.com Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures rise, Absci falls pre-market on worse-than-expected sales. Other stocks declining in pre-market trading.
benzinga.com Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings Activist investor DOMA nominates three directors to Pacira's board, citing weak oversight, missed earnings, and rising executive pay.- benzinga.com Pacira BioSciences Issues Statement In Response To DOMA's Nomination Of Director Candidates; Reaffirms Commitment to Shareholder Value Creation; No Shareholder Action Required At This Time Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual…
- benzinga.com DOMA Perpetual Asserts Pacira BioSciences CEO Frank Lee Should Be Replaced Immediately; Urges Board To Name Interim CEO And Conduct Formal Sale Process Of The Business Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Yearsi; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30%ii; The Company's Underperformance…
- benzinga.com Pacira BioSciences Presents Real-World Evidence From Innovations In Genicular Outcomes Registry At AAOS 2026 Annual Meeting -- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee ---- Data presented…
- benzinga.com Pacira BioSciences Sees FY2026 Sales $745.000M-$770.000M vs $790.214M Est. Pacira BioSciences (NASDAQ:PCRX) sees FY2026 sales of $745.000 million-$770.000 million vs $790.214 million analyst estimate.
benzinga.com Pacira BioSciences Q4 Earnings Assessment - benzinga.com Pacira BioSciences Q4 Adj. EPS $0.57 Misses $0.90 Estimate, Sales $196.873M Miss $200.424M Estimate. Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.57 per share which missed the analyst consensus estimate of $0.90 by 36.95 percent. This is a 37.36 percent decrease over earnings…
- benzinga.com Earnings Scheduled For February 26, 2026